N/A N=20 Telerehabilitation Gait Modification
Osteoarthritis, Knee
Primary: Lab-measured Performance of Gait Modification — 6.32; 5.71; 11.22; 5.64 degrees — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=802 Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening Among Women in Appalachia
Cervical Carcinoma · Human Papillomavirus Infection
Primary: Effectiveness of Human Papillomavirus (HPV) Intervention — 69; 17 Participants
Phase 4 N=25 Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation
Atrial Fibrillation
Primary: Mean Percentage of Time Spent in Atrial Fibrillation — 2.74; 5.85 percentage of time
N/A N=525 A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System
Breast Cancer Female
Primary: Difference in Procedural Time in Minutes — 42.15; 40.13 procedure time in minutes
N/A N=2,868 Increasing Vaccine Uptake Among Adolescents in the Rural South
Vaccine Hesitancy
Primary: Difference in the Percentage of Adolescents Who Ever Received at Least One Dose of HPV Vaccination in the Intervention Group After the Intervention Implementation…
N/A N=12 Continued Access Study VIG Anastomotic Connector
Dialysis Access Malfunction
Primary: Cumulative Patency — 5 Participants
Phase 1 N=20 Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant
Cough · Healthy
Primary: Part 1: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC[0-Infinity]) of Camlipixant — 3851.24; 1423.84 Hours*nanograms per milliliter
N/A N=43 Arena Labs - Improving Clinician Well Being
Mental Health Disorder
Primary: Change in Heart Rate Variability — 39; 47; 54 Milliseconds
N/A N=84 Puff Biofeedback to Reduce Smoking Reinforcement
Cigarette Smoking
Primary: Cigarette Purchase Task- Omax — 18.84; 18.80 cigarettes — p=.71
N/A N=601 Gelatines in Pediatric PatientS
Treatment of Hypovolemia and Shock
Primary: Dosing of the Products During Surgery — 14.58; 12.64 ml/kg
Phase 2 N=25 The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial
Non-small Cell Lung Cancer, NSCLC
Primary: Progression-Free Survival (PFS) — 19 Participants
N/A N=120 Savvy System Project
Caregiver Burnout · Dementia
Primary: Change in Center for Epidemiologic Studies - Depression Scale (CES-D) Score — 13.2; 79 score on a scale
N/A N=52 Rhythmic Light Therapy for Alzheimer's Disease Patients
Mild Cognitive Impairment
Primary: Change in Electroencephalography (EEG) Power at 40 Hertz (Hz) — 3.54; 5.28; 2.83; 4.10 μV2/Hz
Phase 2 N=295 A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
Non-alcoholic Steatohepatitis (NASH)
Primary: Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3)…
Phase 2 N=41 Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
B-Cell Non-Hodgkin Lymphoma · Hematopoietic and Lymphoid Cell Neoplasm · Leukemia
Primary: Number of Participants Experienced Severe Toxicity From Lenalidomide and Ipilimumab Post Transplant — 10; 2 Participants